All patients
subjects at risk
hydroxychloroquine in COVID 19 hospitalized - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results FACCT Trial, 2021 0.69 [0.28; 1.68]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.10 [0.98 ; 1.22 ] FACCT Trial, 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 3 0% 6,823 moderate not evaluable deathsdetailed results Abd-Elsalam, 2020 1.21 [0.36; 4.12]
Chen, 2020 0.56 [0.01; 30.20]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.47 [0.48; 4.52]
FACCT Trial, 2021 0.96 [0.44; 2.08]
NO COVID-19 (Lyngbakken), 2020 0.96 [0.06; 15.78]
NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.11 [0.99 ; 1.23 ] Abd-Elsalam, 2020, Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, FACCT Trial, 2021, NO COVID-19 (Lyngbakken), 2020, NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 8 0% 7,547 moderate not evaluable deaths (time to event analysis only)detailed results NOR-Solidarity (hydroxychloroquine), 2021 3.10 [0.29; 33.20]
RECOVERY, 2020 1.09 [0.97; 1.23]
SOLIDARITY (WHO study) HCQ, 2020 1.19 [0.89; 1.59]
1.11 [0.99 ; 1.23 ] NOR-Solidarity (hydroxychloroquine), 2021, RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 3 0% 6,681 moderate not evaluable clinical deteriorationdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1.21 [0.69; 2.12]
1.21 [0.69 ; 2.12 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 1 0% 332 NA not evaluable clinical improvement (14-day)detailed results Chen, 2020 0.56 [0.13; 2.48]
Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.83 [0.47; 1.44]
0.79 [0.47 ; 1.33 ] Chen, 2020, Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 2 0% 481 moderate not evaluable clinical improvement (time to event analysis only)detailed results FACCT Trial, 2021 0.85 [0.62; 1.16]
0.85 [0.62 ; 1.16 ] FACCT Trial, 2021 1 0% 254 NA not evaluable death or ventilationdetailed results RECOVERY, 2020 1.14 [1.03; 1.27]
SOLIDARITY (WHO study) HCQ, 2020 1.11 [0.87; 1.42]
1.14 [1.03 ; 1.25 ] RECOVERY, 2020, SOLIDARITY (WHO study) HCQ, 2020 2 0% 5,776 moderate not evaluable hospital dischargedetailed results FACCT Trial, 2021 0.88 [0.64; 1.21]
0.88 [0.64 ; 1.21 ] FACCT Trial, 2021 1 0% 254 NA not evaluable viral clearance by day 14detailed results Chen, 2020 1.42 [0.26; 7.76]
1.42 [0.26 ; 7.76 ] Chen, 2020 1 0% 33 NA not evaluable ICU admissiondetailed results Abd-Elsalam, 2020 0.83 [0.35; 1.95]
FACCT Trial, 2021 1.42 [0.79; 2.55]
1.19 [0.72 ; 1.96 ] Abd-Elsalam, 2020, FACCT Trial, 2021 2 4% 448 moderate not evaluable cardiac arrestdetailed results SOLIDARITY (WHO study) HCQ, 2020 1.92 [0.35; 10.49]
1.92 [0.35 ; 10.49 ] SOLIDARITY (WHO study) HCQ, 2020 1 0% 1,853 NA not evaluable adverse eventsdetailed results Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020 0.88 [0.29; 2.65]
RECOVERY, 2020 1.36 [0.98; 1.90]
1.31 [0.95 ; 1.80 ] Coalition Covid-19 Brazil I (Cavalcanti)-Hydroxychloroquine, 2020, RECOVERY, 2020 2 0% 5,048 moderate not evaluable 0.5 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-04-20 04:02 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 95,94,90,91
- treatments: 657,832
- roots T: 290
